Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by AIM ImmunoTech Inc.

AIM ImmunoTech to Report Full Year 2022 Financial Results on March 31, 2023 and Host Inaugural Quarterly Conference Call and Webcast
From AIM ImmunoTech Inc.
Via Globe NewsWire
AIM ImmunoTech Announces Late-Breaking Presentation at the International Conference on Antiviral Research Regarding Ampligen as a Potential Therapy Against Ebola Virus Disease
From AIM ImmunoTech Inc.
Via Globe NewsWire
AIM ImmunoTech Announces Publication of New Analysis of the Mechanism of Action of Ampligen as a Potential Prophylactic Therapy Against Ebola Virus Disease
From AIM ImmunoTech Inc.
Via Globe NewsWire
AIM ImmunoTech Issues Letter to Stockholders
From AIM ImmunoTech Inc.
Via Globe NewsWire
AIM ImmunoTech Announces Phase 2 Study of Ampligen® for the Treatment of Pancreatic Cancer is Open and Recruiting Patients
From AIM ImmunoTech Inc.
Via Globe NewsWire
AIM ImmunoTech to Participate in Solve M.E. and The Biotechnology Innovation Organization (BIO) Virtual Event, “Long Covid: What Will It Take To Accelerate Therapeutic Progress?”
From AIM ImmunoTech Inc.
Via Globe NewsWire
AIM ImmunoTech Enters into Pancreatic Cancer Clinical Research Agreements with AstraZeneca and Erasmus Medical Center
From AIM ImmunoTech Inc.
Via Globe NewsWire
AIM ImmunoTech Broadens Patent Portfolio with New Netherlands Utility Patent Covering Ampligen® and Other AIM-Developed dsRNA Products to Include Rugged dsRNA for Use in COVID-19 Treatment or Prevention
From AIM ImmunoTech Inc.
Via Globe NewsWire
AIM ImmunoTech to Present at the ‘Virtual Investor 2023 Companies to Watch Event’
From AIM ImmunoTech Inc.
Via Globe NewsWire
AIM ImmunoTech Appoints Christopher McAleer, Ph.D. as Scientific Officer
From AIM ImmunoTech Inc.
Via Globe NewsWire
AIM ImmunoTech Reports Positive Safety, Tolerability and Biological Activity Data for Intranasal Ampligen® (Rintatolimod) in Healthy Subjects
From AIM ImmunoTech Inc.
Via Globe NewsWire
AIM ImmunoTech Announces Abstract Accepted for Poster Presentation at the British Society for Immunology Congress 2022
From AIM ImmunoTech Inc.
Via Globe NewsWire
AIM ImmunoTech Reports Third Quarter 2022 Financial Results and Provides Corporate Update
From AIM ImmunoTech Inc.
Via Globe NewsWire
AIM ImmunoTech Announces Presentation of New Data from Roswell Park Comprehensive Cancer Center Evaluating Ampligen® as a Component of a Chemokine-Modulating (CKM) Regimen, with Paclitaxel, for the Treatment of Early-Stage Triple Negative Breast Cancer
From AIM ImmunoTech Inc.
Via Globe NewsWire
AIM ImmunoTech Announces Corporate Governance Enhancements
From AIM ImmunoTech Inc.
Via Business Wire
Tickers AIM
AIM ImmunoTech Shareholders Elect All Three Company Director Nominees at 2022 Annual Meeting
From AIM ImmunoTech Inc.
Via Business Wire
Tickers AIM
AIM ImmunoTech Receives Orphan Drug Designation for Ampligen (rintatolimod) for the Treatment of Ebola Virus Disease
From AIM ImmunoTech Inc.
Via Globe NewsWire
Delaware Court Rules in Favor of AIM ImmunoTech and Declines to Declare Activist Group’s Nominations Valid
From AIM ImmunoTech Inc.
Via Business Wire
Tickers AIM
AIM ImmunoTech Board Issues Letter to Shareholders
From AIM ImmunoTech Inc.
Via Business Wire
Tickers AIM
AIM ImmunoTech Announces FDA Clearance of IND Application to Evaluate Ampligen in Phase 2 Clinical Study for the Treatment of Post-COVID Conditions
From AIM ImmunoTech Inc.
Via Globe NewsWire
AIM ImmunoTech Board Files Definitive Proxy Statement and Sends Letter to Shareholders
From AIM ImmunoTech Inc.
Via Business Wire
Tickers AIM
AIM ImmunoTech Provides Update on Jorgl Activist Group Litigation
From AIM ImmunoTech Inc.
Via Business Wire
Tickers AIM
AIM ImmunoTech Reports Positive Pilot Study Data from Expanded Access Program Evaluating Ampligen® for the Treatment of Long COVID
From AIM ImmunoTech Inc.
Via Globe NewsWire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.